Clinical Genetics & Dementia
|
|
- Lee O’Brien’
- 6 years ago
- Views:
Transcription
1 Clinical Genetics & Dementia Dr Nayana Lahiri Consultant in Clinical Genetics & Honorary Senior Lecturer
2 Aims of the Session To appreciate the potential utility of family history and genetic investigations in the diagnosis of dementia To appreciate the difference between diagnostic and predictive genetic testing To consider the possibilities for genetic testing or DNA storage in your dementia patients
3 Why make a genetic diagnosis? To provide an explanation To access support/care To allow screening/monitoring for other symptoms There may be implications for other family members
4 How do we make a diagnosis? Have common non-genetic causes been excluded? Age at onset upto 10% of dementia cases Phenotype Family History? Other associated features? Diagnostic Testing Single Gene Testing Panel Testing Whole Exome/Genome Sequencing
5 Case 1 72y
6 Alzheimer s Disease Clinical signs Slowly progressive dementia Neuroimaging Gross cerebral cortical atrophy on CT or MRI Diffuse cerebral hypometabolism on PET Cerebrospinal fluid (CSF) Decreased Aβ amyloid 42 and increased tau Neuropathological Findings at postmortem 80-90% concurrence with clinical diagnosis
7 Alzheimer s Disease Lifetime risk of AD is 10-12% Approximately 25% of all AD is familial (i.e., 2 persons in a family) Of which 95% is late onset ( >60-65 years) 5% is early onset (<65 years)
8 Manic depressive psychosis Multifactorial disease Concordance Identical Non-identical (MZ) (DZ) 67% 5% Cleft lip and palate Rheumatoid arthritis Asthma Coronary artery disease 38% 34% 47% 19% 8% 7% 24% 9% Diabetes mellitus 56% Alhzeimer s Disease 55% 11% Both genetic and environmental factors important
9 Genetic susceptibility to disease
10 Early Onset Familial Alzheimer s Mean Onset <65 years Autosomal Dominant Chance of finding a mutation in a simplex case is LOW <6% In one lab the pickup was APP (10-15%) 1.4% PSEN1 (30-70%) 4% PSEN2 (<5%) 1% Other loci Genet Med May; 18(5):
11 Genetic susceptibility to disease
12 Genetic Risk Variants APOE encodes a polymorphic glycoprotein expressed in liver, brain, macrophages, and monocytes. ApoE participates in transport of cholesterol and other lipids and is involved in neuronal growth, repair response to tissue injury, nerve regeneration, immunoregulation, and activation of lipolytic enzymes. The APOE gene contains three major allelic variants at a single gene locus (ɛ2, ɛ3, and ɛ4), encoding for different isoforms (ApoE2, ApoE3, and ApoE4) that differ in two sites of the amino acid sequence.
13 Risks associated with APOE The APOE ɛ4 allele increases risk in familial and sporadic early-onset and late-onset AD x3 risk for APOE ɛ34 x15 for APOE ɛ44 The APOE ɛ2 allele is thought to have a protective effect 20 25% of the general population carries one or more ɛ4 alleles 40 65% of AD patients are ɛ4 carriers. The effect of APOE ɛ4 accounts for 27.3% of the estimated disease heritability of up to 80%
14 Figure 1: Manhattan plot of stage 1 for genome-wide association with Alzheimer's disease (17,008 cases and 37,154 controls). From Nature Genetics 45, (2013) Genetic Risk Variants
15 Direct to Consumer Testing
16 Should we test for risk variants? Up to 75% of individuals heterogeneous for APOE ɛ4 do not develop AD during life Up to 50% of people with AD do not carry the high-risk ɛ4 allele. The case for testing and the risks associated with other genes is even weaker
17 What is the point in finding them? Insight into pathogenic mechanisms Druggable targets Risk stratification in Clinical Trials?
18 Alzheimer s Disease Trials The TOMMORROW trial Phase III trial of pioglitazone to delay the onset of mild cognitive impairment of AD in individuals at high risk. Risk prediction is based on an algorithm including APOE and TOMM40 genotypes.
19 Case 2 Dementia, 80 s?? Schizophrenia onset 30 s Died aged 72 - dementia Psychotic episode, 57yrs Now 68yrs in care home. Progressive dementia with loss of ability to speak.
20 Collateral History Psychotic episode aged 58yrs?Frontal lobe seizures Primary Diagnosis of Alzheimers Disease aged 67yrs PET decreased update in temporal lobe MRI moderate atrophy of parietal lobe Now Behavioural presentation more FTD Poor speech Poor sleep Rapid personality change with outbursts of temper
21 Frontotemporal Dementia Neurodegeneration mainly involving Frontal and Temporal lobes Progressive change in personality and behaviour or progressive deterioration in language abilities 2 major subtypes Behavioural variant FTD (bvftd) Primary progressive aphasia (PPA) which includes progressive nonfluent aphasia, sematic dementia and logpenic aphasia
22 Genetics of FTD Approximately 30% of people with FTD have some family history of dementia In up to 30 of patients with FTD a single high-risk genetic mutation is identified More likely to find a genetic cause in Behavioural Variant C9orf72 most common and not on a gene panel TAU/MAPT GRN Rare genes VCP, CHMP2B, FUS, TARDP, SQSTM1, DCTN1
23 Diagnostic Testing Discussion with Father main carer and power of attourney Very helpful discussion with Consultant Psychiatrist He arranged a blood test Sent for C9orf72 C9orf72 expansion confirmed Follow up appointment arranged
24 Predictive testing Cannot offer predictive testing if the cause in an affected individual is unknown Why do people have predictive testing? - Need to know 55% - Planning life 51% - Reducing uncertainty 19% - Family planning 13% - Factor in marriage / relationship 13%
25 Predictive testing HD guidelines Initial visit discuss FHx, reasons for wanting presymptomatic testing, implications of a positive test, insurance, mortgages.?psychiatric assessment Cooling off period (40% drop out rate here) Second visit and blood test Follow-up with result Seen 2-4 weeks later and thereafter Not for <18yrs (testing of minors) Testing should be delayed in the pregnant or depressed
26 Case 2 Dementia, 80 s?? Schizophrenia onset 30 s Died aged 72 - dementia C9orf72 expansion
27 Case 2 Dementia, 80 s?? Schizophrenia onset 30 s Died aged 72 - dementia C9orf72 expansion Negative result
28
29
30
31
32
33 Take Home Messages Genetic testing and advising on dementia risk remains challenging despite advances in genomic technology. Rapidly advancing genomic technologies are helping develop treatments for dementia. If early-onset dementia with/without a family history consider referral to Specialist Cognitive Neurology Clinic for phenotyping. If in doubt and if practicable, store a DNA sample. Do refer for children/family members to Genetics - but we can t offer predictive testing unless there is an established genetic diagnosis in an affected individual
34 Online Resources
The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer
The frontotemporal dementia spectrum what the general physician needs to know Dr Jonathan Rohrer MRC Clinician Scientist Honorary Consultant Neurologist Dementia Research Centre, UCL Institute of Neurology
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationObjectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit
Objectives RAIN Difficult Diagnosis 2014: A 75 year old woman with falls Alexandra Nelson MD, PhD UCSF Memory and Aging Center/Gladstone Institute of Neurological Disease Recognize important clinical features
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationChapter 18 Genetics of Behavior. Chapter 18 Human Heredity by Michael Cummings 2006 Brooks/Cole-Thomson Learning
Chapter 18 Genetics of Behavior Behavior Most human behaviors are polygenic and have significant environmental influences Methods used to study inheritance include Classical methods of linkage and pedigree
More informationContents. Introduction. Introduction 03
Genes and dementia Introduction This information is for anyone who wants to know more about the link between genes and dementia. This includes people living with dementia, their carers, friends and families.
More informationLANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION
LANGUAGE AND PATHOLOGY IN FRONTOTEMPORAL DEGENERATION Murray Grossman University of Pennsylvania Support from NIH (AG17586, AG15116, NS44266, NS35867, AG32953, AG38490), IARPA, ALS Association, and the
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More informationSupplementary Note. Patient #1 Additional Details
Supplementary Note Patient #1 Additional Details Past medical history: The patient was ambidextrous. She had a history of hypertension, hyperlipidemia, migraines, and remote history of an ANA-positive
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationCorporate Medical Policy Genetic Testing for Alzheimer s Disease
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
More informationMultifactorial Inheritance
S e s s i o n 6 Medical Genetics Multifactorial Inheritance and Population Genetics J a v a d J a m s h i d i F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, Novemb e r 2 0 1 7 Multifactorial
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationMULTIFACTORIAL DISEASES. MG L-10 July 7 th 2014
MULTIFACTORIAL DISEASES MG L-10 July 7 th 2014 Genetic Diseases Unifactorial Chromosomal Multifactorial AD Numerical AR Structural X-linked Microdeletions Mitochondrial Spectrum of Alterations in DNA Sequence
More informationgenetics 101 FTD/PPA Family Caregiver and Professional Education and Support Conference 2012
agenda genetic counseling genetics 101 genetics of FTD and PPA Lisa Kinsley, MS, CGC, genetic counselor HyungSub Shim, MD, neurology fellow, CNADC how does my fit in? what to expect what is a genetic counselor?
More informationWhat is frontotemporal dementia?
What is frontotemporal dementia? Introduction Information in this introductory booklet is for anyone who wants to know more about frontotemporal dementia (FTD). This includes people living with FTD, their
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationDr Fiona Kumfor University of Sydney
Social Cognition in Dementia: Informing Diagnosis, Prognosis and Management Dr Fiona Kumfor University of Sydney CHANGES IN DEMENTIA Memory Social cognition Language ELEMENTS OF SOCIAL COGNITION Face processing
More informationEarly Onset Dementia From the background to the foreground
Early Onset Dementia From the background to the foreground Dr Jeremy Isaacs Consultant Neurologist St George s Hospital Excellence in specialist and community healthcare Themes of my talk The early onset
More informationSandra Weintraub, PhD Clinical Core Leader and Professor
Sandra Weintraub, PhD Clinical Core Leader and Professor Northwestern Cognitive Neurology and Alzheimer s Disease Center (CNADC) Chicago, Illinois www.brain.northwestern.edu Why is it so difficult to diagnose
More informationFrontotemporal Dementia: Towards better diagnosis. Frontotemporal Dementia. John Hodges, NeuRA & University of New South Wales, Sydney.
I.1 I.2 II.1 II.2 II.3 II.4 II.5 II.6 III.1 III.2 III.3 III.4 III.5 III.6 III.7 III.8 III.9 III.10 III.11 III.12 IV.1 IV.2 IV.3 IV.4 IV.5 Frontotemporal Dementia: Towards better diagnosis Frontotemporal
More informationDo not copy or distribute without permission. S. Weintraub, CNADC, NUFSM, 2009
Sandra Weintraub, Ph.D. Clinical Core Director, Cognitive Neurology and Alzheimer s Disease Center Northwestern University Feinberg School of Medicine Chicago, Illinois Dementia: a condition caused by
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationRuolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce
Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce ALESSANDRO MARTORANA UOC NEUROLOGIA-CENTRO ALZHEIMER POLICLINICO TOR VERGATA-UNIVERSITÀ DI ROMA TOR VERGATA
More informationI do not have any disclosures
Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo
More informationDementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology
More informationGenetics and Genomics in Medicine Chapter 8 Questions
Genetics and Genomics in Medicine Chapter 8 Questions Linkage Analysis Question Question 8.1 Affected members of the pedigree above have an autosomal dominant disorder, and cytogenetic analyses using conventional
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationreview of existing studies on ASL in dementia Marion Smits, MD PhD
review of existing studies on ASL in dementia Marion Smits, MD PhD Associate Professor of Neuroradiology Department of Radiology, Erasmus MC, Rotterdam (NL) Alzheimer Centre South-West Netherlands, Rotterdam
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationWhat is. frontotemporal. address? dementia?
What is frontotemporal address? dementia? Contents 03 What is frontotemporal dementia? 04 Symptoms 05 Diagnosis 06 Treatments Information in this booklet is for anyone who wants to know more about frontotemporal
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationGenetics of dementia. Contents. Factsheet 405LP May 2016
Genetics of dementia Factsheet 405LP May 2016 Many people will be concerned about whether dementia can be inherited that is, passed down from an affected relative. People with dementia might be worried
More informationBiomarkers: Translating Research into Clinical Practice
Biomarkers: Translating Research into Clinical Practice AFTD Education Conference San Diego, April 2015 Nadine Tatton, PhD Scientific Director, AFTD HelpLine 866-5507-7222 u info@theaftd.org u www.theaftd.org
More informationClinical Policy Title: Genetic testing for Alzheimer s disease
Clinical Policy Title: Genetic testing for Alzheimer s disease Clinical Policy Number: 02.01.20 Effective Date: July 1, 2016 Initial Review Date: May 18, 2016 Most Recent Review Date: May 19, 2017 Next
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name Amyotrophic Lateral Sclerosis 10 (ALS10) and Amyotrophic Lateral Sclerosis 6 (ALS6)
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationMultifactorial Inheritance. Prof. Dr. Nedime Serakinci
Multifactorial Inheritance Prof. Dr. Nedime Serakinci GENETICS I. Importance of genetics. Genetic terminology. I. Mendelian Genetics, Mendel s Laws (Law of Segregation, Law of Independent Assortment).
More informationPaper Title Theme Presentation Type Poster Presentatio n Day
A NOVEL PROBE OF FUNCTIONAL NETWORK ARCHITECTURE IN PROTEINOPATHIES: SPECTRAL DCM IN SEMANTIC DEMENTIA Blood and imaging biomarkers Poster and Data Blitz Monday 1 M1 PATHWAYS PREDICTION & RISK-GENE PRIORITIZATION
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. It has been identified that there are over 200 subtypes of
More informationNCRAD. Single Gene Implicated in FTD/ALS UCSF Memory and Aging Center, San Francisco, California
The National Cell Repository for Alzheimer s Disease (NCRAD) is a data and specimen collection source for families with Alzheimer disease (AD) or serious memory loss. Families having two or more living
More informationEvaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:
Alzheimer s Disease A Public Health Response July 19, 2007 1 2 Guest Speakers Thanks to our Sponsors: Earl A. Zimmerman, M.D. Bender Endowed Chair of Neurology and Director of the Alzheimer s Center at
More informationMedical Policy. MP Genetic Testing for Alzheimer Disease
Medical Policy MP 2.04.13 BCBSA Ref. Policy: 2.04.13 Last Review: 04/30/2018 Effective Date: 4/30/2018 Section: Medicine Related Policies 2.04.14 Biochemical Markers of Alzheimer Disease 6.01.55 β-amyloid
More informationDiabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More informationNeuro degenerative PET image from FDG, amyloid to Tau
Neuro degenerative PET image from FDG, amyloid to Tau Kun Ju Lin ( ) MD, Ph.D Department of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital ( ) Department of Medical Imaging
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationAlzheimer s Disease Neuroimaging Initiative
Alzheimer s Disease Neuroimaging Initiative Steering Committee Meeting April 18, 2016 Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Table 1. Participants Autopsied
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationPhenotypic Variability in ALS
Phenotypic Variability in ALS Michael A. Elliott, MD, FAAN Medical Director, ALS Clinic Swedish Neuroscience Institute 1 Outline ALS Background Description Typical Presentation Clinical Phenotype Motor
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationCommon Forms of Dementia Handout Package
Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationFTD/PPA Caregiver Education Conference March 11, 2011
FTD/PPA Caregiver Education Conference March 11, 2011 Question and Answer Session Answered by Joseph Cooper, MD, Darby Morhardt, MSW, LCSW, Mary O Hara, AM, LCSW, Jaimie Robinson, MSW, LCSW, Emily Rogalski,
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationEpilepsy in dementia. Case 1. Dr. Yotin Chinvarun M..D. Ph.D. 5/25/16. CEP, PMK hospital
Epilepsy in dementia Dr. Yotin Chinvarun M..D. Ph.D. CEP, PMK hospital Case 1 M 90 years old Had a history of tonic of both limbs (Lt > Rt) at the age of 88 years old, eye rolled up, no grunting, lasting
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationPerspectives on Frontotemporal Dementia and Primary Progressive Aphasia
Perspectives on Frontotemporal Dementia and Primary Progressive Aphasia Bradley F. Boeve, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Alzheimer s Disease
More informationDementia Past, Present and Future
Dementia Past, Present and Future Morris Freedman MD, FRCPC Division of Neurology Baycrest and University of Toronto Rotman Research Institute, Baycrest CNSF 2015 Objectives By the end of this presentation,
More informationImaging Genetics: Heritability, Linkage & Association
Imaging Genetics: Heritability, Linkage & Association David C. Glahn, PhD Olin Neuropsychiatry Research Center & Department of Psychiatry, Yale University July 17, 2011 Memory Activation & APOE ε4 Risk
More informationHow can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationClinical Policy Title: Genetic testing for Alzheimer s disease
Clinical Policy Title: Genetic testing for Alzheimer s disease Clinical Policy Number: 02.01.20 Effective Date: July 1, 2016 Initial Review Date: May 18, 2016 Most Recent Review Date: April 10, 2018 Next
More informationWhat is dementia? Symptoms of dementia. Memory problems
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. The brain is made up of nerve cells (neurones) that communicate
More informationGenetics of Behavior (Learning Objectives)
Genetics of Behavior (Learning Objectives) Recognize that behavior is multi-factorial with genetic components Understand how multi-factorial traits are studied. Explain the terms: prevalence, incidence,
More informationLecture 42: Final Review. Martin Wessendorf, Ph.D.
Lecture 42: Final Review Martin Wessendorf, Ph.D. Lecture 33 cortex Heilbronner 5 lobes of the cortex Lateral view (left side) Mid-saggital view (right side) Cellular organization of cortex White matter
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationDementia Training Session for Carers. By Dr Rahul Tomar Consultant Psychiatrist
Dementia Training Session for Carers By Dr Rahul Tomar Consultant Psychiatrist Dementia in the UK: Facts & Figures National Dementia strategy launched in 2009 800,000 people living with dementia (2012)
More informationPolicy #: 011 Latest Review Date: May 2017
Name of Policy: Genetic Testing for Alzheimer s Disease Policy #: 011 Latest Review Date: May 2017 Category: Laboratory/Pathology Policy Grade: A Background/Definitions: As a general rule, benefits are
More informationJay M. Baraban MD, PhD January 2007 GENES AND BEHAVIOR
Jay M. Baraban MD, PhD jay.baraban@gmail.com January 2007 GENES AND BEHAVIOR Overview One of the most fascinating topics in neuroscience is the role that inheritance plays in determining one s behavior.
More informationObjectives. Objectives continued: 3/24/2012. Copyright Do not distribute or replicate without permission 1
Frontotemporal Degeneration and Primary Progressive Aphasia Caregiver and Professional Education Conference Diana R. Kerwin, MD Assistant Professor of Medicine-Geriatrics Cognitive Neurology and Alzheimer
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationResearch ALZHEIMER S DISEASE AND RISK FACTORS
Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the
More informationClinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort
doi:10.1093/brain/awv358 BRAIN 2016: 139; 452 467 452 Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort Sara Van Mossevelde, 1,2,3,4 Julie van
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationThe role of the vascular system in dementia
The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDan Koller, Ph.D. Medical and Molecular Genetics
Design of Genetic Studies Dan Koller, Ph.D. Research Assistant Professor Medical and Molecular Genetics Genetics and Medicine Over the past decade, advances from genetics have permeated medicine Identification
More informationAlzheimer Disease and Complex Segregation Analysis p.1/29
Alzheimer Disease and Complex Segregation Analysis Amanda Halladay Dalhousie University Alzheimer Disease and Complex Segregation Analysis p.1/29 Outline Background Information on Alzheimer Disease Alzheimer
More informationDementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings
Dementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings Chapter 4.2 N. Tolboom E.L.G.E. Koedam J.M. Schott M. Yaqub M.A. Blankenstein F. Barkhof Y.A.L. Pijnenburg A.A. Lammertsma
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationNIH Public Access Author Manuscript Semin Neurol. Author manuscript; available in PMC 2014 November 14.
NIH Public Access Author Manuscript Published in final edited form as: Semin Neurol. 2013 September ; 33(4): 386 416. doi:10.1055/s-0033-1359312. Neuroimaging Biomarkers of Neurodegenerative Diseases and
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
diagnosis and assessment bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published.
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationFrontotemporal Dementia
Frontotemporal Dementia clinical, genetic, and pathological heterogeneity Harro Seelaar The studies in this thesis were funded by: Stichting Dioraphte Hersenstichting Nederland Prinses Beatrix Fonds Nuts
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. There are over 200 subtypes of dementia, but the five most
More information